Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy
Voyager Therapeutics (Nasdaq: VYGR) will present three posters at the 29th Annual Congress of the European Society of Gene & Cell Therapy from October 11-14, 2022, in Edinburgh, Scotland.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Voyager Therapeutics (Nasdaq: VYGR) will present three posters at the 29th Annual Congress of the European Society of Gene & Cell Therapy from October 11-14, 2022, in Edinburgh, Scotland. The presentations focus on advancements in AAV gene therapy, including an engineered BBB-penetrant capsid family and evaluations of dose-response and production methodologies for AAV-based therapies. These developments may enhance treatment for neurological disorders, showcasing the company's commitment to innovation in gene therapy.
Positive
- Presentation of three posters at a significant industry conference highlights the company's research and innovation in gene therapy.
- Focus on advancements in AAV capsid technology may position Voyager Therapeutics favorably within the gene therapy market.
Negative
- None.
Details
News Market Reaction – VYGR
The recorded move for VYGR in the trading session of this news was -4.90%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced that it will present three posters at the upcoming 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), taking place October 11-14, 2022, in Edinburgh, Scotland.
Poster Presentation Details:
Presentation Title: Identification of a Cell Surface Receptor Utilized by an Engineered BBB-Penetrant Capsid Family with Enhanced Brain Tropism in Non-Human Primates and Mice
Poster Number: P024
Presenting Author: Brett Hoffman, Ph.D., Senior Scientist, Capsid Discovery
Presentation Title: Dose-Response Evaluation of 9P801, an Engineered AAV Capsid with High BBB Penetration and CNS Transduction in Non-Human Primates
Poster Number: P015
Presenting Author: Mathieu Nonnenmacher, Ph.D., Vice President, Capsid Discovery
Presentation Title: Evaluation of an Early, Late, Very Late Expressed Rep in a Recombinant Baculovirus to Produce a More Potent AAV-based Gene Therapeutic in Insect Cells
Poster Number: P065
Presenting Author: Jeffrey Slack, Ph.D., Principal Scientist, Cell Culture Development
About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the modality to treat devastating diseases. Proprietary capsids born from the Company’s TRACER discovery platform are powering a rich early-stage pipeline of programs and may elevate the field to overcome the narrow therapeutic window associated with conventional gene therapy vectors across neurologic disorders and other therapeutic areas. voyagertherapeutics.com LinkedIn Twitter
Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.
Contacts
Investors
Investors@vygr.com
Media
Peg Rusconi
prusconi@vergescientific.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.